Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value.
Frail Leukemia Patients See Better Results With New Blood Monitoring
This single-center retrospective analysis evaluated long-course venetoclax combined with hypomethylating agents in unfit AML patients. Resul…
A new look at blood tests shows how well frail leukemia patients respond to standard treatment.
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work.
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…